Benzinga | Mar 10, 2021 07:33AM EST

Biohaven's NURTEC ODT Approved In Israel For Acute Treatment Of Migraine

NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven") and Medison Pharma announced today that NURTEC(r) ODT (rimegepant) was approved by the Israeli Ministry of Health for the acute treatment of migraine with and without aura in adults. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.